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Other Gynecologic Cancer. This semiannual international journal is
dedicated to providing practicing physicians and health care profes-
sionals with the most up-to-date, clinically relevant information
available to help them provide only the highest quality care for their
patients with gynecologic cancer. It is my privilege to serve as the
newly appointed Editor of this journal.
The care of women with ovarian or other gynecologic cancers has
evolved significantly over the past couple of decades. Diagnostic tests
are now available to help identify women who have a genetic predis-
position for ovarian or endometrial cancer or who may harbor cervi-
cal dysplasia. Advancements in surgical techniques now allow for
more radical debulking of both upper abdominal and pelvic disease
in women with advanced ovarian cancer. Laparoscopic and robotic
surgical techniques have revolutionized the surgical approaches to
patients with endometrial and cervical cancer.
Advances in conformal and intensity-modulated radiation therapy
now allow radiation oncologists to target pelvic tumor tissues more spe-
cifically and spare normal tissues. The development of new chemother-
apy agents and new delivery approaches has improved progression-free
survival in patients with ovarian and other gynecologic cancers. New
biological agents such as antiangiogenesis agents andPARP inhibitors, as
well as others, have demonstrated promising antitumor effects.
Yet despite these advances, there is still much work to do before we
can realize real and significant improvement in the survival of so many
womenwhose lives are cut short by ovarian or other gynecologic cancers.
What are the key steps that will help achieve this worthwhile goal?
First, there is a need to ensure that all patients with ovarian and
gynecologic cancers get the highest quality care currently available.
Recent data would suggest that a substantial number of newly diag-
nosed patients with ovarian cancer are not receiving what would be
considered standard therapy. Addressing these and other disparities
is complicated but must be addressed if we are to see patients with
gynecologic cancer achieve the best possible outcome.
Second, there is a need to increase our understanding of the bio-
logical characteristics of ovarian and other gynecologic cancers. Re-
cent breakthroughs in high-throughput technology are being used to
further elucidate the biological features of ovarian and other gyneco-
logic cancers. The Cancer Genome Atlas project in the past year
published the results of their analysis of a cohort of patients with
high-grade serous epithelial ovarian cancer. This study provided new
insights into the number of molecular pathways involved in high-
grade serous tumors, the leading cause of mortality in ovarian cancer.
Other studies are elucidating the molecular pathways and alterations
in the tumor microenvironment involved in other epithelial ovarianAs the biological characteristics of gynecologic cancers are further
elucidated, therewill be aneed todevelop strategies to target the involved
molecular processes. Innovative clinical trials will be needed to test the
efficacyof these targeted agents in smaller subsets of patients so thatmore
personalized approaches to treat an individual patient, based on that
individual’s unique tumor profile, can be identified.
Finally, advances in genetics and in the molecular consequences of
lifestyle choices will allow for opportunities to identify additional
women at risk for gynecologic cancer and for novel strategies to either
prevent or improve outcomes in women at risk for, or diagnosed
with, gynecologic cancers. Indeed, many countries are dealing with
an obesity epidemic that puts many women at risk for various gyne-
cologic cancers or negatively affects outcome in women diagnosed
with gynecologic cancer.
Thus, how can this journal best help our readership at present to
enhance the quality of care for their patients at risk or for those
diagnosed with gynecologic cancer and to keep up with the afore-
mentioned steps that will lead to important breakthroughs in the
prevention and treatment of gynecologic cancer?We will accomplish
this goal by using 3 primary measures. We will first provide review
articles on the detection, diagnosis, prevention, and treatment of
gynecologic cancers. Such reviews should reach out to more practi-
tioners and provide them with the most current guidelines regarding
the management of patients at risk for, or diagnosed with, gyneco-
logic cancer. Reviews on new cutting-edge scientific discoveries will
also be published frequently. Our journal will also publish debates on
controversial topics in gynecologic oncology, particularly when there are
major disagreements regarding the various options available to manage
patients with gynecologic cancer. Finally, Clinical Ovarian and Other
Gynecologic Cancer will continue to publish original research articles fo-
cusing primarily on clinical and translational research in gynecologic
cancer and unique gynecologic cancer case reports.
The journal is indebted to Dr. Tate Thigpen who has served as its
Editor since its inception in 2008 under the title of Clinical Ovarian
Cancer and other Gynecologic Malignancies.Dr. Thigpen worked dil-
igently to get this journal off the ground. The early issues were dom-
inated by content that he personally solicited. We could not have
reached this point without his strong vision for and dedication to this
journal. It wasmy privilege to serve withDr. Thigpen over the past year
as co-Editor and before that as an Associate Editor. I will do my best as
the new Editor along with my new Deputy Editor, Dr. Paul Sabbatini,
to help our journal deliver practical information that practitioners will
find useful in determining how best to manage patients risk for, or
diagnosed with, ovarian or other gynecologic cancers.Ronald D. Alvarez
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